All In Biotech

Drug Trial Radar · NCT06403267

NoNO-42 Trial in Acute Ischemic Stroke Patients Selected for Thrombolysis With or Without Endovascular Thrombectomy

A Multicentre, Prospective, Randomized, Open Label, Blinded-Endpoint, Placebo-controlled, Single-dose Trial to Determine the Efficacy and Safety of NoNO-42 in Participants With Acute Ischemic Stroke Selected for Thrombolysis With or Without Endovascular Thrombectomy (ACT-42 Trial)

Last checked: Nov 19, 2026Latest source record: Jul 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Oct 2, 2024

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
NoNO Inc.Industry
Sponsor type
Industry
Collaborators
University of Calgary
First posted
May 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ACT-42 is a domain of the ACT-GLOBAL platform (NCT06352632). This trial is a Phase 2b, multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled single-dose adaptive trial. A total of up to 600 male and female participants aged ≥ 18 to ≤ 90 years harboring an acute ischemic stroke who are eligible for an intravenous thrombolytic with or without endovascular thrombectomy therapy will be enrolled within 4.5 hours of stroke onset/last known well.

Conditions

  • Acute Ischemic Stroke

Interventions

  • NoNO-42Drug

    a single dose sterile 20 ml vial containing lyophilized powder for reconstitution containing 300 mg of NoNO-42 active ingredient.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Reducing global disability in participants with acute ischemic stroke (AIS)Time frame: 90 days from intervention

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • University of Calgary - Foothills Medical Centre

    Calgary, Alberta, Canada · Recruiting

  • University of Alberta Hospital

    Edmonton, Alberta, Canada · Recruiting

  • Vancouver General Hospital

    Vancouver, British Columbia, Canada · Recruiting

  • University of Manitoba

    Winnipeg, Manitoba, Canada · Recruiting

  • Hamilton General Hospital

    Hamilton, Ontario, Canada · Recruiting

  • Ottawa Hospital Research Institute

    Ottawa, Ontario, Canada · Recruiting

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, Canada · Recruiting

  • Unity Health Toronto, St. Michael's Hospital

    Toronto, Ontario, Canada · Recruiting

  • Royal University Hospital

    Saskatoon, Saskatchewan, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.